Navigation Links
Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
Date:9/9/2010

ANN ARBOR, Mich., Sept. 9 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca. The patent claims are directed to the use of anastrozole in combination with an estrogen and a progestin and protect Meditrina's endometriosis product MPI-676.

"The allowance of this patent to our licensor AstraZeneca is a significant step forward in the protection of our approach to treating endometriosis with our proprietary endometriosis product, MPI-676," said Thomas A. Collet, president and CEO. "This patent also extends protection for MPI-676 in the world's largest pharmaceutical market in addition to Europe, Australia, China, Indonesia and South Africa, where patents have issued already."  

Endometriosis is a serious medical condition where endometrial stroma and glands that are normally present in the uterine cavity are found in other parts of the body.  Endometriosis lesions can be found anywhere in the pelvic cavity.  The most common symptom of endometriosis is pelvic pain, which often correlates to the menstrual cycle, but a woman with endometriosis may also experience pain that doesn't correlate to her cycle.  For many women, the pain of endometriosis is so severe and debilitating that it significantly impacts their daily lives.

It is estimated that seven to 10 percent of all women are affected by endometriosis, including 70 to 87 percent of women with chronic pelvic pain and 30 to 40 percent of all infertile women.  Chronic pelvic pain, dysmenorrhea (painful period
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... HUATULCO, Mexico , July 3, 2015 ... targeting the epidemics of hypertension, diabetes and thyroid disorders ... online educational platforms and a major conference dedicated to ... Manage Diabetes Online , Manage Hypertension ... each developed and operated by EXCEMED - ...
(Date:7/2/2015)... -- Pharma Major Lupin Limited anunció ... ZAO "Biocom" en Rusia bajo ciertas condiciones de ... en el mercado farmacéutico de Rusia que registró ... uno de los 10 principales mercados farmacéuticos del ... una década, el mercado farmacéutico ruso registró un ...
(Date:7/2/2015)... ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2015 results on Thursday, July 30, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Latin America With Medical Education 2Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2
... MEMPHIS, Tenn., Sept. 9 The National,Coalition ... the proposed cuts to,the HIV/AIDS Medi-Cal pilot ... medications for thousands of Californians living with,HIV/AIDS. ... of recent studies,demonstrating that these pharmacy services ...
... Sept. 9 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) ... Company,s lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the ... Palms Resort & Convention Center in Orlando., ... Date/Time: Tuesday, October 7, 2008 from 10:30 a.m. - ...
Cached Medicine Technology:NCPS Outraged at HIV/AIDS Medi-Cal Cuts 2Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
(Date:7/3/2015)... ... 2015 , ... Scientists at several top US cancer centers believe they now ... Click here to read the complete story , just posted on the Surviving ... Medical Center, and New York University exposed mice with a mutation on the tumor ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... healthcare providers, has been retained to lead a national president recruitment ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... place on June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel ... to injured bicyclists and practical points of investigating these types of cases. , ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits ... Cancer Lawsuit Center website. Just as the previous version did, the new website will ... lawsuit updates and ovarian cancer warning information. The site is routinely updated with news ...
(Date:7/3/2015)... ... 2015 , ... First Choice Emergency Room , the largest network of ... the new Medical Director of its Frisco facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
Breaking Medicine News(10 mins):Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3
... About ten years ago, the discovery of microRNAs ― ... unlocked a world of scientific possibilities, including a deeper ... "deep sequencing," which gives scientists the ability to discover ... Now, Tel Aviv University researchers have developed the cutting-edge ...
... departments when they,ve broken a leg, been stabbed or ... the Stanford University School of Medicine finds that 90 ... The high prevalence was surprising, said M. Kit Delgado, ... at Stanford,s Center for Primary Care and Outcomes Research, ...
... in daycare puts children with a chronic lung condition ... infections, according to a study from Johns Hopkins Children,s ... . The researchers say their findings should ... of age, for signs of lung disease and to ...
... HealthDay Reporter , SATURDAY, Sept. 25 (HealthDay News) ... as much water as they should, and the deficiency ... "Even mild dehydration can affect physiological function, and cause ... Heller, clinical nutrition coordinator at the Center for Cancer ...
... Lillian Feldshuh, of Scarsdale, NY, an early recipient of ... Patient Award yesterday at the Transcatheter Cardiovascular Therapeutics (TCT ... a success and Feldshuh, who will turn 100 years ... In 2006, Lillian Feldshuh suffered from aortic stenosis, a ...
... of the major disease states in the developed world. But ... You may experience stress as something that affects your entire ... if we zoom in on the building bricks of the ... differently. Stress can arise at the cellular level after exposure ...
Cached Medicine News:Health News:Diving deeper into the gene pool 2Health News:Preventive care poses dilemma for emergency departments, Stanford study finds 2Health News:Preventive care poses dilemma for emergency departments, Stanford study finds 3Health News:Daycare puts children with lung disease at risk for serious illness 2Health News:U.S. Kids Drink Too Little Water: Study 2Health News:U.S. Kids Drink Too Little Water: Study 3Health News:Stress can control our genes 2
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... ToRCH Plus Control is a ... monitor the performance of the ... and assays. A weak positive ... you to monitor the performance ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: